Glycogen storage disease type I surgery: Difference between revisions
Jump to navigation
Jump to search
Line 18: | Line 18: | ||
** 10 year survival rate of 64% | ** 10 year survival rate of 64% | ||
*There is resolution of metabolic derangements (correction of hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia) after liver transplantation in patients with GSD type 1.<ref name="pmid18471553">{{cite journal| author=O'Leary JG, Lepe R, Davis GL| title=Indications for liver transplantation. | journal=Gastroenterology | year= 2008 | volume= 134 | issue= 6 | pages= 1764-76 | pmid=18471553 | doi=10.1053/j.gastro.2008.02.028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18471553 }} </ref> | *There is resolution of metabolic derangements (correction of hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia) after liver transplantation in patients with GSD type 1.<ref name="pmid18471553">{{cite journal| author=O'Leary JG, Lepe R, Davis GL| title=Indications for liver transplantation. | journal=Gastroenterology | year= 2008 | volume= 134 | issue= 6 | pages= 1764-76 | pmid=18471553 | doi=10.1053/j.gastro.2008.02.028 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18471553 }} </ref> | ||
*"Model for end-stage liver disease” (MELD) score is used to govern priority for liver transplantation | *"Model for end-stage liver disease” (MELD) score is used to govern priority for liver transplantation.<ref name="pmid12512033">{{cite journal| author=Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P et al.| title=Model for end-stage liver disease (MELD) and allocation of donor livers. | journal=Gastroenterology | year= 2003 | volume= 124 | issue= 1 | pages= 91-6 | pmid=12512033 | doi=10.1053/gast.2003.50016 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12512033 }} </ref> | ||
*The score range between 6 and 40 and is calculated using a logarithmic assessment of three objective and reproducibe variables including: | |||
**Total serum bilirubin | |||
**Creatinine concentrations | |||
**International normalized ratio | |||
==References== | ==References== |
Revision as of 17:49, 9 November 2017
Glycogen storage disease type I Microchapters |
Differentiating Glycogen storage disease type I from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type I surgery On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type I surgery |
Directions to Hospitals Treating Glycogen storage disease type I |
Risk calculators and risk factors for Glycogen storage disease type I surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Liver transplantation is the final treatment for patients with metabolic disease associated associated with GSD type 1.
Indications
Indications for liver transplantation include:[1]
- Patients with multifocal
- Growing lesions that do not regress with improved dietary regimens
- Patients who do not have evidence of distant metastatic disease.
Surgery
- Liver transplantation may improve the survival of patients with glycogen storage disease type 1.
- Survival rates of patients after liver transplantation are:[2]
- 1 year survival rate of 82%
- 5 year survival rate of 76%
- 10 year survival rate of 64%
- There is resolution of metabolic derangements (correction of hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia) after liver transplantation in patients with GSD type 1.[3]
- "Model for end-stage liver disease” (MELD) score is used to govern priority for liver transplantation.[4]
- The score range between 6 and 40 and is calculated using a logarithmic assessment of three objective and reproducibe variables including:
- Total serum bilirubin
- Creatinine concentrations
- International normalized ratio
References
- ↑ Kishnani, Priya S.; Austin, Stephanie L.; Abdenur, Jose E.; Arn, Pamela; Bali, Deeksha S.; Boney, Anne; Chung, Wendy K.; Dagli, Aditi I.; Dale, David; Koeberl, Dwight; Somers, Michael J.; Burns Wechsler, Stephanie; Weinstein, David A.; Wolfsdorf, Joseph I.; Watson, Michael S. (2014). "Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics". Genetics in Medicine. doi:10.1038/gim.2014.128. ISSN 1098-3600.
- ↑ Maheshwari A, Rankin R, Segev DL, Thuluvath PJ (2012). "Outcomes of liver transplantation for glycogen storage disease: a matched-control study and a review of literature". Clin Transplant. 26 (3): 432–6. doi:10.1111/j.1399-0012.2011.01549.x. PMID 22066793.
- ↑ O'Leary JG, Lepe R, Davis GL (2008). "Indications for liver transplantation". Gastroenterology. 134 (6): 1764–76. doi:10.1053/j.gastro.2008.02.028. PMID 18471553.
- ↑ Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P; et al. (2003). "Model for end-stage liver disease (MELD) and allocation of donor livers". Gastroenterology. 124 (1): 91–6. doi:10.1053/gast.2003.50016. PMID 12512033.